Oscar Health is a must-buy because its CEO is buying while the market misprices a short-term headwind, and CEOs can see one to two quarters ahead. x.comÂ
Sylent Capital
Stock Trader, Indicator Toolkit & Trade Signals
Oscar Health's CEO bought $12 million of stock near the lows, an eight-figure insider buy worth paying attention to. Shares are now at 5.5-year highs and close to threatening the all-time high set at the IPO price. x.comÂ
Oscar Health's CEO bought $12 million of stock, a move that could stop the shares' six-month slide. x.comÂ
Oscar Health looks too extended after its big move and should pull back around earnings in the next few days; it is not a tech stock with a niche product capable of parabolic moves. x.comÂ
Oscar Health has the most room to run among health insurers, which are rallying after the administration announced increased Medicaid budgets. CEO Mark Bertolini bought about $12 million of shares at the lows, the first insider purchase this year, and Oscar's market cap is just $3.74B. The chart confirms it: a broken daily descending trendline, surging money flow and a volume spike. Resistance sits at $14.15-$15, and a close above $15 brings the 200-day moving average into play. x.comÂ
Oscar Health's run has just started. The market liked the CEO buying stock, the reaffirmed 2026 guidance and last quarter's first-ever operating profit. x.com x.comÂ
Hyped growth stocks can be poor investments even when their businesses grow, because valuations already assume they will become exceptional. Retail buyers often arrive after the promise is widely recognized, before tougher competition separates lasting winners from the rest. Eight of the nine previously warned-about stocks have fallen, though Oscar Health has gained. x.comÂ
Oscar Health is shifting from story stock to genuine profitability as membership growth drives operating leverage. Its SG&A ratio fell from 15.8% to 15.2%, and CMS cut ACA exchange user fees, easing costs for an insurer reliant on that market. CEO Mark Bertolini bought 1 million shares for $11.92M in April, signaling confidence in a profitability inflection. ICHRA, where employers fund employees' own coverage, is a large untapped market, and its new Lucie shopping platform deepens its moat. … Show more
Oscar Health looks like a steal at a market cap of around $9 billion. It generated $4.6 billion in revenue last quarter with more than $600 million in net income. x.comÂ
Oscar Health cannot be a great business because insurance, like banking, is uninvestable when its economics are nearly impossible to predict. One bad cycle or change in costs can wipe out margins that are already nonexistent. A post the author replies to argues Oscar avoided the 30-40% member drop the market expected after enhanced premium tax credits expired. x.comÂ
Oscar Health is valued at less than 1x trailing sales, a wild valuation for a business still growing at its pace. It generated $11 billion of revenue last year and trades at a market cap of roughly $9 billion. x.comÂ